Enliven Therapeutics, Inc.
ELVN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $18,225 | $21,491 | $24,895 | $20,724 |
| G&A Expenses | $6,871 | $7,093 | $6,798 | $6,172 |
| SG&A Expenses | $6,871 | $7,093 | $6,798 | $6,172 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $25,096 | $28,584 | $31,693 | $26,896 |
| Operating Income | -$25,096 | -$28,584 | -$31,693 | -$26,896 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $4,948 | $3,249 | $3,149 | $3,716 |
| Pre-Tax Income | -$20,148 | -$25,335 | -$28,544 | -$23,180 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$20,148 | -$25,335 | -$28,544 | -$23,180 |
| % Margin | – | – | – | – |
| EPS | -0.32 | -0.49 | -0.57 | -0.46 |
| % Growth | 34.7% | 14% | -23.9% | – |
| EPS Diluted | -0.32 | -0.49 | -0.57 | -0.46 |
| Weighted Avg Shares Out | 62,094 | 52,105 | 50,051 | 49,858 |
| Weighted Avg Shares Out Dil | 62,094 | 52,105 | 50,051 | 49,858 |
| Supplemental Information | – | – | – | – |
| Interest Income | $4,948 | $3,251 | $3,196 | $3,716 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $62 | $81 | $74 | $80 |
| EBITDA | -$20,086 | -$28,503 | -$31,619 | -$26,816 |
| % Margin | – | – | – | – |